Oppenheimer analyst Francois Brisebois maintained a Buy rating on Durect (DRRX – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $1.07.
According to TipRanks, Brisebois is an analyst with an average return of -3.0% and a 37.18% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Aquestive Therapeutics, and Dyne Therapeutics.
Durect has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
The company has a one-year high of $7.46 and a one-year low of $0.47. Currently, Durect has an average volume of 143.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Durect (DRRX) Company Description:
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
Read More on DRRX:
- DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
- Options Volatility and Implied Earnings Moves Today, May 13, 2024
- DRRX Upcoming Earnings Report: What to Expect?
- DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Durect reports Q4 EPS (10c), consensus (33c)
